Showing 3921-3930 of 5771 results for "".
- Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officerhttps://modernod.com/news/aerie-pharmaceuticals-appoints-raj-kannan-as-chief-executive-officer/2480519/Aerie Pharmaceuticals announced that Raj Kannan will join the company as Chief Executive Officer and a director, effective December 20, 2021. “On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search pro
- Jeff Sieve Appointed CEO of Haag-Streit USAhttps://modernod.com/news/jeff-sieve-appointed-ceo-of-haag-streit-usa/2480518/Haag-Streit has announced that Jeff Sieve is the new Chief Executive Officer for Haag-Streit USA. Mr. Sieve begins his new role immediately, succeeding Ernest Cavin, PhD, who recently left the company to pursue new opportunities. Mr. Sieve will report to Haag-Streit Group management, le
- NTC and I-MED Pharma Partner to Bring HA-based Dry Eye Ointment to the United States Markethttps://modernod.com/news/ntc-and-i-med-pharma-partner-to-bring-ha-based-dry-eye-ointment-to-the-united-states-market/2480516/NTC Srl and I-MED Pharma announced today that I-Defense, a lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the FDA. It is the first European NTC medical device prod
- Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunologyhttps://modernod.com/news/aramis-biosciences-launches-to-address-unmet-needs-in-ocular-immunology/2480514/Aramis Biosciences announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including i
- Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Diseasehttps://modernod.com/news/kiora-reports-kio-101-is-safe-and-tolerable-for-dry-eye-disease/2480512/Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safe
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st
- I-MED Pharma USA Gains Exclusive Distribution Rights for ESW Vision’s E>Eye and Tearcheck in the United Stateshttps://modernod.com/news/i-med-pharma-usa-gains-exclusive-distribution-rights-for-esw-visions-eeye-and-tearcheck-in-the-united-states/2480505/I-MED Pharma has announced the expansion of their strategic partnership with ESW Vision in France to be their exclusive distributor in the United States. Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country. E>Eye i
- Recently Approved Presbyopia Eye Drop Vuity Now Available in Pharmacieshttps://modernod.com/news/recently-approved-presbyopia-eye-drop-vuity-now-available-in-pharmacies/2480503/Allergan announced that Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the FDA to treat presbyopia, is now available by prescription in pharmacies nationwide. "We are pleased to be able to bring this first-of-its
- AcuFocus Receives Approvable Letter From FDA for IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-receives-approvable-letter-from-fda-for-ic-8-small-aperture-iol/2480498/AcuFocus announced receipt of an Approvable Letter from the FDA for its IC-8
- Aerie Signs License Agreement With Santen for Rhopressa and Rocklatan in Europe and Several Other Regionshttps://modernod.com/news/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressa-and-rocklatan-in-europe-and-several-other-regions/2480495/Aerie Pharmaceuticals announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expan